These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 34688987)
21. Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy. Xu G; Liu K; Chen X; Lin Y; Yu C; Nie X; He W; Karin N; Luan Y Nanoscale Horiz; 2024 Jan; 9(2):295-304. PubMed ID: 38086653 [TBL] [Abstract][Full Text] [Related]
22. Injectable Supramolecular Hydrogels for In Situ Programming of Car-T Cells toward Solid Tumor Immunotherapy. Zhu C; Ke L; Ao X; Chen Y; Cheng H; Xin H; Xu X; Loh XJ; Li Z; Lyu H; Wang Q; Zhang D; Ping Y; Wu C; Wu YL Adv Mater; 2024 Feb; 36(5):e2310078. PubMed ID: 37947048 [TBL] [Abstract][Full Text] [Related]
23. Kim J; Francis DM; Thomas SN Nanomaterials (Basel); 2021 Feb; 11(2):. PubMed ID: 33673289 [TBL] [Abstract][Full Text] [Related]
24. Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Cheng F; Su T; Zhou S; Liu X; Yang S; Lin S; Guo W; Zhu G Sci Adv; 2023 Jul; 9(28):eade6257. PubMed ID: 37450588 [TBL] [Abstract][Full Text] [Related]
25. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. Shirinbak S; Chan RY; Shahani S; Muthugounder S; Kennedy R; Hung LT; Fernandez GE; Hadjidaniel MD; Moghimi B; Sheard MA; Epstein AL; Fabbri M; Shimada H; Asgharzadeh S Oncoimmunology; 2021 Jan; 10(1):1838140. PubMed ID: 33489468 [TBL] [Abstract][Full Text] [Related]
26. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME). Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604 [TBL] [Abstract][Full Text] [Related]
27. Functional Gadofullerene Nanoparticles Trigger Robust Cancer Immunotherapy Based on Rebuilding an Immunosuppressive Tumor Microenvironment. Li L; Zhen M; Wang H; Sun Z; Jia W; Zhao Z; Zhou C; Liu S; Wang C; Bai C Nano Lett; 2020 Jun; 20(6):4487-4496. PubMed ID: 32407113 [TBL] [Abstract][Full Text] [Related]
28. In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy. Wang F; Xie M; Huang Y; Liu Y; Liu X; Zhu L; Zhu X; Guo Y; Zhang C Angew Chem Int Ed Engl; 2024 Jan; 63(4):e202315282. PubMed ID: 38032360 [TBL] [Abstract][Full Text] [Related]
29. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Chao Y; Liang C; Tao H; Du Y; Wu D; Dong Z; Jin Q; Chen G; Xu J; Xiao Z; Chen Q; Wang C; Chen J; Liu Z Sci Adv; 2020 Mar; 6(10):eaaz4204. PubMed ID: 32181368 [TBL] [Abstract][Full Text] [Related]
30. Injectable cold atmospheric plasma-activated immunotherapeutic hydrogel for enhanced cancer treatment. Fang T; Cao X; Shen B; Chen Z; Chen G Biomaterials; 2023 Sep; 300():122189. PubMed ID: 37307777 [TBL] [Abstract][Full Text] [Related]
31. Comment on "An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy". Lin L; Zhang S; Yang W Small; 2024 May; 20(18):e2302812. PubMed ID: 38072801 [TBL] [Abstract][Full Text] [Related]
32. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
33. Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel-Mediated Reprogramming of Cancer-Associated Fibroblasts in Osteosarcoma. Wang H; Chen Y; Wei R; Zhang J; Zhu J; Wang W; Wang Z; Wupur Z; Li Y; Meng H Adv Mater; 2024 Apr; 36(15):e2309591. PubMed ID: 38113900 [TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
35. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence. Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618 [TBL] [Abstract][Full Text] [Related]
36. Encapsulation of 10-hydroxy camptothecin in supramolecular hydrogel as an injectable drug delivery system. Li R; Shu C; Wang W; Wang X; Li H; Xu D; Zhong W J Pharm Sci; 2015 Jul; 104(7):2266-75. PubMed ID: 25980666 [TBL] [Abstract][Full Text] [Related]
37. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment. Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712 [TBL] [Abstract][Full Text] [Related]
38. Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy. Hu M; Zhang J; Yu Y; Tu K; Yang T; Wang Y; Hu Q; Kong L; Zhang Z Small; 2020 Dec; 16(50):e2004905. PubMed ID: 33206460 [TBL] [Abstract][Full Text] [Related]
39. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190 [TBL] [Abstract][Full Text] [Related]
40. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. Ye Y; Wang J; Hu Q; Hochu GM; Xin H; Wang C; Gu Z ACS Nano; 2016 Sep; 10(9):8956-63. PubMed ID: 27599066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]